Lifeward and Ottobock Care Test a Scalable U.S. Access Model for ReWalk 7
Lifeward and Ottobock Care are testing a six-month U.S. access model for ReWalk 7. The significance is less about new hardware and more about the clinical, reimbursement and support infrastructure required to turn coverage into actual personal exoskeleton use.
The Exoskeleton Market in 2026: Size, Growth, Companies and Adoption Trends
The exoskeleton market is moving from research and pilots toward commercial scale. This evidence-led 2026 analysis explains market size, industrial and medical adoption, consumer mobility, listed companies, major investments, funding rounds and the outlook to 2030.